In accordance with a resolution from the 2015 Annual General Meeting the Nomination Committee shall consist of the Chairman of the Board and one representative for each of the three largest shareholders in terms of voting rights at the end of September 2015. Since September 2015 two changes have occurred among the owners of EQL Pharma, which affects the composition of the Nomination Committee, i.e. Batten AB has reduced its holdings and is now outside of the top three list, while Cadila Pharma has become the second largest owner in EQL Pharma.

For the 2016 Annual General Meeting the Nomination Committee consists of:

Christer Fåhraeus, (Christer Fåhraeus and companies), Rajiv I Modi (appointed by Cadila Pharma), Karin Wehlin (appointed by Karin Wehlin and companies), and the Chairman of the Board, Ingemar Kihlström.

Shareholders wishing to submit proposals to the Nomination Committee may send an email to info@eqlpharma.com.

For more information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB in short

EQL Pharma is specialized in development and sales of generics, i.e. pharmaceuticals that are medically equivalent to original pharmaceuticals. The company is currently marketing five niche generics on the Swedish and Danish markets and in addition has a significant pipeline of niche generics for launch from 2016 and onwards. The company is currently focusing on prescription medicines in the Nordic countries. EQL Pharma’s registered office is in Lund, Sweden, employs 6 (7) people and is listed on AktieTorget. EQL Pharma conducts extensive developmental work in collaboration with leading contract manufacturers and major pharmaceutical companies in e.g. India and China.